Exercise Trial for Alzheimer's Disease
Alzheimer's DiseaseExercise Trial for Alzheimer's Disease(EXTRA) is a pilot randomized clinical trial involving a physcial activity program versus a healthy lifestyle program, with one year follow-up in 30 non-disabled, community-dwelling persons, age 65 and older.
Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease
Alzheimer's DiseaseThe purpose of this study is to determine whether ORM-12741 is safe and effective in the treatment of Alzheimer's disease.
An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of...
Alzheimer's DiseaseThis study will be a single-center, open-label, randomized, 3-treatment crossover study of single oral doses of an API-capsule formulation of E2609 under fasted conditions and a tablet formulation administered under fed and fasted conditions in healthy subjects.
Delta-THC in Dementia
Behavioural DisturbancesPain3 moreThis is a phase II, randomized, placebo-controlled, double-blind, parallel-group, multicentre study to the efficacy and safety of low dose delta-9-THC in behavioural disturbances and pain in patients with mild to severe dementia, when added to an analgesic treatment with acetaminophen. It is hypothesized that Namisol® will lead to more behavioural disturbances than placebo, when added to an analgesic treatment with acetaminophen, and as measured by a change in Neuropsychiatric Inventory (NPI) score, after a three week treatment period. It is expected that this will be due, primarily, to psychoactive effects of Namisol® and secondary to a reduction in pain sensation (as measured with VRS and PACSLAC-D). It is expected that a reduction in NPS will positively affect quality of life and lead to better functioning in daily living.
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease...
Alzheimer's DiseaseThe purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
Safety and Efficacy of MT-4666
Alzheimer's DiseaseThe objective of this study is to evaluate the safety and efficacy as assessed by the Alzheimers Disease Assessment Scale-cognitive subscale 13-item (ADAS-cog-13) of two doses of MT-4666 or placebo administered daily for 24 weeks to subjects with mild to moderate Alzheimer's disease.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of...
Alzheimer's DiseaseThe current study will examine the safety, tolerability, plasma pharmacokinetics (PK), and plasma pharmacodynamics (PD) of single-doses of GSK2647544.The study will be conducted as a randomized, single-blind, placebo controlled, 4-way crossover single oral ascending dose design in 2 independent cohorts, eight healthy male subjects in each of the cohorts. Each potential subject will undergo Screening visit, Treatment Phase and Follow-up visit.
Enhancing Neuroplasticity and Frontal Lobe Function in Patients With Mild Alzheimer's Disease
Alzheimer's DiseaseThe purpose of this study is to determine if a novel brain stimulation approach using magnetic stimulation (Transcranial Magnetic Stimulation [TMS]) can improve memory and thinking processes in individuals with mild Alzheimer's disease (AD).
Masitinib in Patients With Mild to Moderate Alzheimer's Disease
Alzheimer DiseaseThe purpose of this study is to assess the safety and efficacy of masitinib for the treatment of mild to moderate Alzheimer's Disease. Masitinib will be administered as add-on therapy in patients who have been treated for a minimum of 6 months with a stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine.
S-Equol in Alzheimer's Disease (SEAD) Trial
Alzheimer's DiseaseThe purpose of this study is to determine if S-equol could benefit persons with Alzheimer's Disease (AD).